• Sp1;
  • glioma;
  • prognosis;
  • invasion;
  • MMP-2


  1. Top of page
  2. Abstract
  3. Material and Methods
  4. Results
  5. Discussion
  6. References

Sp1, the first identified transcription factor, has been reported to be associated with the development and progression of various human cancer types. However, the clinical significance and biological role of Sp1 in glioma are less well understood. In this study, we found that the expression of Sp1 was markedly elevated in glioma cell lines and tissues. Immunohistochemistry analysis revealed that the vast majority of 222 paraffin-embedded archival glioma specimens tested displayed positive Sp1 expression, and 58.6% exhibited high-level Sp1 expression. Statistical analysis suggested that the high Sp1 expression was correlated strongly with the WHO grading (p < 0.001) and survival status (p < 0.001) of glioma patients. Patients with lower Sp1 expression had better overall survival than those with higher Sp1 expression. Multivariate analysis suggested that Sp1 expression might be an independent prognostic indicator of the survival of patients with glioma. Furthermore, overexpression of Sp1 in glioma cells was found to increase their invasiveness, and in contrast, silencing Sp1 by siRNA caused an inhibition of cell invasion. Moreover, we demonstrated that the up-regulation of Sp1 could increase activity and expression of MMP-2. Collectively, our data suggest that Sp1 might represent a valuable prognostic marker for glioma and is involved in modulation of tumor invasion.

Glioma is the most common central nervous system tumor in adults. Despite that great progress has been made in the surgical, radioactive and chemical antiglioma modalities, the prognosis of the disease remains poor, with the 5-year survival rate for glioblastoma multiforme being only 2%.1, 2 While the molecular pathology responsible for the aggressiveness of human glioma and the suboptimal response to conventional therapies is largely unknown, existing data suggest that a diversity of biological changes in glioma cells may account for the poor overall survival of patients with glioma.3 Understanding these molecular characteristics that are associated with the development, progression and response or resistance to therapies will bring new insights into gliomagenic mechanisms and new therapeutic strategies.

Specificity protein 1 (Sp1) is the first identified transcription factor that activates a broad spectrum of cellular and viral genes.4 Sp1 protein recognizes different but related G-rich motifs and interacts with DNA through 3 C2H2-type zinc fingers located at the C-terminus.5 A mass of evidence has shown that Sp1 plays a pivotal role in the regulation of multiple genes that have been recognized to be important for tumorigenesis.6 In a number of human cancer types, including breast cancer,7 thyroid tumor,8 gastric cancer,9 epidermal squamous cell carcinoma10 and pancreatic cancer,11 elevation of Sp1 expression has been reported, in some of which Sp1 overexpression is associated with poor clinical outcome.9, 11 To our knowledge, however, no study has examined the expression of Sp1 and its impact on the outcome of glioma patients.

The poor clinical outcome of glioma is largely due to their infiltrating nature and recurrence at adjacent or distant regions in the brain.12 Degradation of extracellular matrix (ECM) and basement membrane, catalyzed by proteases, is a crucial step for a tumor to invade, and matrix metalloproteinases (MMPs) are major proteolytic enzymes involved in degradation of these barriers.13 Human glioma cells express a variety of MMPs, among which MMP-2 and MMP-9 are believed to most effectively degrade most of ECM components.14 Increased expression of MMP-2 and MMP-9 have been strongly implicated in the invasion of various types of human cancers.15, 16 Our recent study showed that MMP-9 gene transcription can be activated by a mechanism involving the astrocyte elevated gene-1 (AEG-1) protein and promotes AEG-1 induced glioma invasion.17 MMP-2 has been found to be overexpressed and correlate with tumor invasion in glioma.13, 14 The mechanisms that activates MMP-2 gene transcription in human glioma cells, however, are still to be elucidated. Notably, the 5′ regulatory region of human MMP-2 gene contains a number of cis-acting elements, including Sp1, Sp3, and Ap-2. Moreover, Pan and coworkers18 have shown that Sp1 plays a key role in controlling MMP-2 expression in lung cancer. These studies suggest a possible involvement of Sp1 in the regulation of MMP-2 gene transcription and consequently the molecular mechanism mediating the invasive and angiogenic phenotype of glioma cells.

In this study, we examined the expression of Sp1 in human glioma and investigated the biological role of Sp1 in promoting the progression of the disease. Our results showed that Sp1 was upregulated in both glioma cell lines and glioma tissues and correlated inversely with the clinical outcome. Furthermore, we found that Sp1 induced invasion of glioma cells through transactivating the expression of MMP-2. Taken together, the data derived from this study provide a basis for further clarification of the molecular mechanism underlying the invasion ability of glioma cells and for future development of new therapeutic strategies.

Material and Methods

  1. Top of page
  2. Abstract
  3. Material and Methods
  4. Results
  5. Discussion
  6. References

Cell lines and reagents

Primary normal human astrocytes (NHA) were purchased from the Sciencell Research Laboratories (Carlsbad, CA) and cultured according to the instruction of the manufacturer. Glioma cell lines LN-18, LN-382, U87MG, U251MG, LN-444, SNB19, U118MG and LN-428 were a kind gift from Dr. Shi-Yuan Cheng (Department of Pathology, University of Pittsburg) and maintained in DMEM supplemented with 10% FBS. MMP-2 inhibitor I (Cis-9-Octadeconyl-N- hydroxylamide, OA-Hy) was purchased from Calbiochem (San Diego, CA).

Patients and tissue specimens

This study was conducted on a total of 222 paraffin-embedded glioma specimens, which were histopathologically diagnosed at the First Affiliated Hospital of Sun Yat-Sen University from 2000 to 2005. Five biopsy specimens of human gliomas (Sample 1, WHO Grade III; Sample 2, WHO Grade IV; Sample 3, WHO Grade II; Sample 4, WHO Grade II; Sample 5, WHO Grade III) and the matched adjacent non-cancerous brain tissues were collected, frozen and stored in liquid nitrogen until assayed. Informed consent from patients and ethics approval from the Institutional Research Ethics Committee were achieved. Clinical information of the samples is presented in detail in Table 1. Normal brain tissues were taken from individual donations died in traffic accidents and confirmed to be free of any detectable pathological conditions.

Table 1. Clinicopathologic characteristics of 222 patient samples and expression of Sp1
inline image

Western blotting

Western blotting (WB) was performed according to a standard method as described previously.19 The following primary antibodies were purchased: anti-Sp1 (Upstate, Lake Placid, NY) and anti-α-tubulin (Sigma-Aldrich, Saint Louis, MO).


Immunohistochemistry (IHC) analysis was performed to study altered protein expression in human glioma and normal tissues. The degree of immunostaining of Sp1 protein was evaluated and scored independently by 2 observers as previous described, considering both the proportion of positive staining tumor cells and the staining intensity.19 Scores representing the proportion of positive stained tumor cells was graded as: 0 (no positive tumor cells), 1 (<10%), 2 (10–50%), and 3 (>50%). The intensity of staining was determined as: 0 (no staining); 1 (weak staining), 2 (moderate staining) and 3 (strong staining). The staining index (SI) was calculated as the product of staining intensity and percentage of positive tumor cells, resulting in scores as 0, 1, 2, 3, 4, 6 and 9. Cutoff values for Sp1 were chosen based on a measurement of heterogeneity using the log-rank test with respect to overall survival. We identified the optimal cutoff as: the SI score of ≥4 was considered as high Sp1 expression, and ≤3 as low expression of Sp1.

IHC staining for protein expression in tumor and normal tissues was quantitative analyzed with the AxioVision Rel.4.6 computerized image analysis system assisted with the automatic measurement program (Carl Zeiss, Oberkochen, Germany). Briefly, to assess the Mean Optical Density (MOD), which represents the strength of staining signals by measuring per positive pixels, we evaluated the stained sections at 200× magnification and ten representative staining fields of each section were analyzed.

Plasmid and generation of stable cell lines

Ectopic expression of Sp1 in glioma cells was achieved using a retroviral gene delivery method. Briefly, human Sp1 cDNA was cloned into retroviral transfer plasmid pMSCV to generate Sp1 expression vector, co-transfecting with the pIK packaging plasmid in 293FT cells by using standard calcium phosphate transfection method as previously described.20 Totally, 36 hr after the cotransfection, supernatants were collected and incubated with LN-18 and LN-382 cells for 24 hr in the presence of polybrene (2.5 μg/mL). Following transduction, puromycin (1.5 μg/mL) was used as a selection antibiotic to select the infected cells for 10 days. Expression of the Sp1 was tested by WB analysis.

Silencing endogenous Sp1 with siRNA

Sp1 specific siRNA oligonulciotides were purchased from Ribobio (Guangzhou, China). siRNA sequences of sense strands are as follows: Sp1-siRNA1, 5′-GGCUGGUGGUGAUGGAAUAdTdT-3′; and Sp1-siRNA2, 5′-GGCUGGUGGUGAUGGAAUAdTdT-3′. siRNA was transfected into cells cultured in 6-well plates using Lipofectamine 2000 following the manufacturer's instructions (Invitrogen, Carlsbad, CA). Following transfection with siRNA, cells were cultured for 2 days before use.

Transwell invasion assay

Cell invasion assays were performed using an in vitro Matrigel assay as described previously.17 Briefly, Transwell inserts for 24-well plates (Corning Costar Corp., Cambridge, MA) were coated with prediluted Matrigel (BD Biosciences, Bedford, MA) and allowed to gel at 37°C for 30 min. Cells were seeded at a density of 3 × 105 per insert and the lower chamber of the Transwell was filled with 500 μL DMEM supplemented with 10% FBS. After 24 hr of incubation, cells remaining on the upper surface of the Transwell membrane were removed by a cotton swab. Cells that had invaded through the Matrigel to the bottom of the insert were fixed, stained, photographed and quantified by counting them in 6 random high-powered fields.

Gelatin zymography

MMP-2 expression in conditioned medium of Sp1 overexpressed or knocked down glioma cells was analyzed by gelatin zymography as previously described.17

RNA extraction and real-time RT-PCR

RNA extraction, RT and real-time PCR were performed as described previously.19 Sequences of the primers and probes are as follows: MMP-2 forward primer 5′-TGAGCTATGG ACCTTGGGAGAA-3′, MMP-2 reverse primer 5′-CCAT CGGCGTTCCCATAC-3′, and MMP-2 probe 5′-FAM-CCAA GTGGTCCGTGTGA-TAMRA-3′; GAPDH forward primer 5′-GACTCATGACCACAGTCCATGC-3′, GAPDH reverse primer 5′-AGAGGCAGGGATGATGTTCTG-3′, and GAPDH probe 5′-FAM-CATCACTGCCACCCAGAAGACTGTG-TA MRA-3′. Expression data were normalized to the geometric mean of housekeeping gene GAPDH to control the variability in expression levels and calculated as 2-[(CTofSp1/MMP-2)(CTofGAPDH)], where CT represents the threshold cycle for each transcript.

Statistical analysis

All statistical analyses were carried out using the SPSS 11.0 statistical software package. The relationship between Sp1 expression and the clinicopathologic characteristics was assayed by the χ2 test. The Spearman rank correlation coefficients were calculated to determine the bivariate correlations between study variables. The Kaplan-Meier method was used to construct the survival curves and the survival differences were compared by the log-rank test. Using multivariate Cox regression analyses to verify the independent effect of each variable involved in this study. Continuous data were compared using Student's t test. In all cases, p < 0.05 was considered statistically significant.


  1. Top of page
  2. Abstract
  3. Material and Methods
  4. Results
  5. Discussion
  6. References

Expression of Sp1 in glioma cell lines and in paired glioma and nontumorous tissues

To investigate the expression levels of Sp1 protein in glioma cell lines, WB analysis was done in NHA and glioma cell lines LN-18, LN-382, U87MG, U251MG, LN-444, SNB19, U118MG and LN-428. All 8 cell lines showed higher level expression of Sp1 protein than that in the NHA (Fig. 1a). To further determine whether Sp1 is also overexpressed in clinical samples of human glioma, WB analysis was conducted with 5 pairs of matched glioma tissue and nontumorous tissue adjacent to the malignant lesion, with each pair obtained from a same patient. As shown in Figure 1b, compared with their paired adjacent nontumorous tissues from the same patient, Sp1 was found to be overexpressed in all 5 examined human glioma samples. Thus, our data indicate that Sp1 was upregulated in glioma and might represent a significant molecular feature of glioma pathogenesis.

thumbnail image

Figure 1. Upregulation of Sp1 in both glioma cell lines and glioma tissues correlates inversely with the clinical outcome. (a) Expression of Sp1 protein in NHA and cultured glioma cell lines LN-18, LN-382, U87MG, U251MG, LN-444, SNB19, U118MG, and LN-428. (b) Expression of Sp1 in paired primary glioma (T) and adjacent noncancerous brain tissues (N), with each pair obtained from a same patient. (c) Representative images from IHC assays of paraffin-embedded specimens of a total of 4 normal brain tissue and 222 primary glioma tissue specimens, including WHO Grades I to IV. i and ii, normal brain tissue; iii and iv, WHO Grade I; v and vi, WHO Grade II; vii and viii, WHO Grade III; ix and x, WHO Grade IV. i, iii, v, vii and ix, 200 x amplification; ii, iv, vi, viii, and x, ×400 amplification. (d) Comparative quantification of the MOD of Sp1 staining among normal brain tissues (4 cases) and glioma specimens of different WHO grades (15 random cases per grade). Mean MOD of Sp1 staining increases as glioma progresses to higher grades. *p < 0.05. (e) Kaplan-Meier curves with univariate analysis (log-rank) for patients with high Sp1-expressing (dotted line) versus low Sp1-expressing (bold line). The cumulative 3-year survival rate is 56.4% in the low Sp1-expression group (n = 39), compared with 27.2% in the high Sp1-expression group (n = 81). (f, g) Kaplan-Meier analysis showing the overall survival of glioma patients categorized according to the WHO grading criteria and status of Sp1 expression. The survival is significantly different between Sp1 high- and low-expressing patients within subgroups of WHO Grades I + II (f) and III + IV (g). For (e), (f), and (g), p values were calculated with the log-rank test. [Color figure can be viewed in the online issue, which is available at]

Download figure to PowerPoint

Expression of Sp1 in archival glioma tissues

Based on the above observation that Sp1 was upregulated both in 8 glioma cell lines and in 5 glioma tumor specimens, we further examined, using IHC, the expression pattern of Sp1 in 222 paraffin-embedded, archived glioma tissues (including 25 cases of Grade I, 61 cases of Grade II, 90 cases of Grade III, and 46 cases of Grade IV). As shown in Figure 1c, Sp1 protein was found to be upregulated in all grades of human glioma compared with that in normal brain tissue. Notably, the subcellular location of Sp1 was detected mainly in the nucleus. Furthermore, quantitative analysis verified that average staining of Sp1 in Grades I to IV tumors was significantly higher than that in normal brain tissue (p < 0.05; Fig. 1d). As summarized in Table 1, Sp1 protein was detectable in 210 of 222 (94.6%) examined glioma cases, with 130 cases (58.6%) displaying high level expression of Sp1.

Correlation between Sp1 protein expression and glioma clinicopathologic features

To further the understanding of the role of Sp1 in the development of glioma, we next analyzed the correlation between Sp1 expression level and clinicopathologic features of glioma patients. While no significant correlation between the Sp1 protein expression and the age (p = 0.905) or sex (p = 0.107) of glioma patients (Table 2) was found, the expression of Sp1 closely correlated with WHO grading (p < 0.001) or survival status of glioma patients (p < 0.001). Moreover, Spearman correlation analysis further revealed that the Sp1 protein expression was positively correlated with WHO grades of glioma (r = 0.263, p < 0.001). Taken as a whole, these data support the notion that the progression of glioma is associated with increased Sp1 expression.

Table 2. Correlation between clinicopathologic features and expressions of Sp1 in glioma patients
inline image

Survival analysis

Kaplan-Meier analysis using the log-rank test was performed to calculate the effect of Sp1 expression on glioma patients' survival (Fig. 1e). The result showed that high expression of Sp1 was markedly associated with a reduced overall survival (p < 0.001). The median survival time of patients with high Sp1 expression (30.87 months, 95% confidence interval: 26.05–35.68) was significantly shorter than that of patients who had low Sp1 expression level (51.90 months, 95% confidence interval: 43.16–60.63). Moreover, the cumulative 3-year survival rate was 56.4% in the low Sp1 expression group, whereas it was only 27.2% in the high Sp1 expression group. We next investigated whether Sp1 expression represented an independent prognostic factor for glioma. Univariate analysis of individual variables revealed strong relationships between overall survival and age (p = 0.006), WHO grade (p < 0.001), and Sp1 expression (p < 0.001). Furthermore, multivariate analysis confirmed Sp1 expression (HR, 2.218; 95% CI, 1.164–4.225; p = 0.015) and WHO grade (HR, 4.410; 95% CI, 2.225–8.740; p < 0.001) as significant prognostic factors for glioma (Table 3).

Table 3. Univariate and multivariate analysis of different prognostic parameters in patients with glioma by Cox-regression analysis
inline image

We next assessed the prognostic significance of expression level of Sp1 protein in different subgroups of glioma patients stratified according to the WHO grading. Notably, high Sp1 expression also significantly correlated with shorter overall survival time in different glioma subgroups. Overall survival of patients with high Sp1 expressing tumors was significantly decreased than those with tumors expressing low levels of Sp1 in either Grades I+II subgroup (n = 44; p = 0.019, log-rank; Fig. 1f) or Grades III+IV subgroup (n = 76; p = 0.016, log-rank; Fig. 1g). Moreover, the number of patients of low- and high-Sp1 expression in each WHO grade is as following: Grade I, low expression: 10, high expression: 4; Grade II, low expression: 18, high expression: 12; Grade III, low expression: 10, high expression: 44; and Grade IV, low expression: 2, high expression: 20. These data collectively suggest that Sp1 expression level strongly and significantly correlate with the prognosis of glioma and the disease outcome.

Effect of Sp1 on glioma cell invasion

To investigate whether and how Sp1 impacts on the aggressive nature of glioma cells, LN-18 and LN-382 glioma cells were engineered to overexpress Sp1 (Fig. 2a) and tested for their ability of invasion. As shown in Figures 2c and 2e, Sp1 overexpression efficiently promoted glioma cells invasion as demonstrated by using the Matrigel invasion assay. To further demonstrate the role of endogenous Sp1 in glioma cell invasion, the effect of Sp1 knockdown on glioma cell invasion was examined. Knockdown of Sp1 expression by specific siRNA1 (Fig. 2b) markedly inhibited the invasive capability of LN-18 and LN-382 glioma cells (Figs. 2d and 2f), suggesting that Sp1 plays a role in the development of the invasion ability of glioma cells.

thumbnail image

Figure 2. Over-expression of Sp1 promotes the invasion of LN-18 and LN-382 glioma cells by inducing MMP-2. (a) Over-expression of Sp1 in glioma cell lines. Sp1 expression is compared by WB using α-tubulin as a loading control. (b) WB assay demonstrates Sp1 expression in LN-18 and LN-382 glioma cells transduced with mock or Sp1-siRNA1. (c) LN-18-vector, LN-18-Sp1, LN-382-vector and LN-382-Sp1 cells were seeded on Matrigel-coated polycarbonate filters to analyze their invasive potentials. Cells were then incubated for 24 hr and the number of cells that invade through filters were stained and counted under microscope. (d) Cell invasion assay of mock- or Sp1-siRNA1-transduced glioma cells. Cells invading across the Matrigel inserts membrane were stained, counted and photographed. (e) Glioma cells with overexpressed Sp1 exhibit a significantly higher level of invasion compared against the control group. (f) The percentages of invaded cells were markedly decreased in Sp1-silenced glioma cells. For e and f, values (mean ± SD) are the mean numbers of cells per 6 fields per membrane of 3 separate experiments, and are expressed as percentage of control. *p < 0.05.

Download figure to PowerPoint

Induction of MMP-2 expression by Sp1

To further analyze the molecular mechanism via which Sp1 enhances glioma cell invasion, we compared the activity of MMP-2 in control and Sp1-overexpressing cells by using zymography assays. As shown in Figure 3a, Sp1 overexpression significantly enhanced the enzyme activity of MMP-2, indicating a possible correlation between MMP-2 expression and the function of transcription factor Sp1. Indeed, real time RT-PCR showed that ectopic expression of Sp1 resulted in increased MMP-2 mRNA expression (Fig. 3c). In contrast, depletion of endogenous Sp1 caused markedly decreased activity and mRNA level of MMP-2 (Figs. 3b and 3d). Furthermore, it is of interest that when the MMP-2 activity was suppressed by a specific inhibitor, as shown in Figure 3e, the enhancing effect of Sp1 on glioma cell invasion was negated, suggesting that MMP-2 may be required for Sp1 induced glioma cell invasion.

thumbnail image

Figure 3. Downregulation of Sp1 expression decreases the invasion of glioma cells by inhibition of MMP-2. (a) Conditioned media were prepared by incubating control or Sp1-infection in serum-free media for 24 hr. MMP-2 activities in Sp1-overexpressing and control glioma cells are analyzed by gelatin zymography. (b) Gelaltin zymography analysis of serum-free conditioned medium from LN-18-mock, LN-18-Sp1-siRNA1, LN-382-mock, and LN-382-Sp1-siRNA1 cells. (c) and (d) Cellular mRNA levels of MMP-2 in indicated cells were analyzed by real time RT-PCR using GAPDH as loading control. *p < 0.05. (e) Matrigel invasion assays were performed in the presence, or absence, of the MMP-2 inhibitor, OA-Hy (20 μmol/L). *p < 0.05.

Download figure to PowerPoint


  1. Top of page
  2. Abstract
  3. Material and Methods
  4. Results
  5. Discussion
  6. References

The present study shows, for the first time, that Sp1 is overexpressed in human glioma, and that the Sp1 overexpression is significantly associated with the clinical and pathological features, as well as the prognosis, of the disease. Together with this finding, we also have demonstrated that Sp1 might promote the invasiveness of glioma cells, possibly through upregulating MMP-2 expression.

Our study adds to the current understanding on the role of Sp1 in tumorigenesis and progression of malignant tumors. With its central regulatory role in many pathways, many of which are associated with oncogenesis, such as cell proliferation, resistance to apoptosis, cell invasion and angiogenesis, Sp1 may be a powerful predictor of the outcome of glioma patients. Sp1 overexpression has been reported in several cancer types. Moreover, Sp1 was indicated as an independent predictor of patients survival.9, 11 Its connection with human glioma, however, has remained unknown. Evidence in support of such a connection, provided by our current study, includes positive results of Sp1 detection in 8 glioma cell lines, in tumor tissues paired with adjacent nontumorous tissue controls, and in the vast majority of a cohort of 222 archived clinical glioma specimens. Further support for a possible role of Sp1 in glioma pathogenesis derived from the analysis that revealed a strong correlation of Sp1 expression with the histopathological staging and inversely, with the survival of the disease. These data not only suggest that Sp1 is likely to be biologically involved in the progression of glioma, but also might represent a valuable independent prognostic biomarker for the disease.

While this study has provided strong evidence for the upregulation of Sp1 in glioma, the molecular mechanism underlying the observed Sp1 upregulation is yet to be elucidated. Sp1 overactivation during tumor development and progression has been shown to be mediated by genetic and epigenetic pathways.21, 22 Nicolás et al. have previously demonstrated that Sp1 protein regulates its own promoter,23 therefore the Sp1 gene can be autoregulated. In addition, Sp1 is regulated by interaction with other proteins, among them prominent oncogenes and tumor suppressors. For example, binding of MDM2 (mouse double minute 2) to C-terminal domain of Sp1 suppresses the DNA-binding capability of Sp1.24 Furthermore, pRb can abolish this suppression by releasing Sp1 from the MDM2-Sp1 complex, thus restoring its DNA binding capability. Moreover, at the protein level, DNA-binding activity and transactivation potential of Sp1 are modulated by several post-translational modifications, including phosphorylation, acetylation, glycosylation, ubiquitylation, sumoylation and poly(ADP-ribosyl)ation.25 Therefore, either increased gene expression or posttranslational modification can cause Sp1 overactivation. Further studies that aim at delineating the mechanisms of Sp1 regulation in glioma will improve our understanding not only of the function of Sp1 but also of gliomagenesis and are underway in the laboratory.

There have been studies addressing how Sp1 influences the outcome of several other cancers. In a previous report, for instance, Yao and coworkers9 have demonstrated that deregulated Sp1 expression plays an important role in gastric cancer tumorigenesis by enhancing VEGF expression. In the scenario of glioma, a biologically and clinically relevant cause for the high mortality lies in their capability to invade extensively within the brain.12 Invasion of glioma cells is a multistep process involving cancer cell attachment to ECM, degradation of ECM components and subsequent infiltration of into adjacent brain tissue.26 The accomplishment of this process, as shown by several lines of research, is largely attributable to the activation of MMPs.27 On the other hand, compelling evidence has linked the up-regulation of Sp1 protein to enhanced invasion of cells of various types of solid tumors.28–30 Our study demonstrates the pathological role of Sp1 in enhancing MMP-2 expression and mediating the invasive phenotype of human glioma cells. However, as a transcription factor, Sp1 plays critical roles in the metastasis of many tumor types by regulating various MMP family members. For example, several lines of evidence suggest that the transcription factor Sp1 is required for constitutive MMP-9 gene expression in various cancer types.31, 32 Sroka et al.'s studies implicated a role for Sp1 in regulating constitutive levels of membrane type-1 matrix metalloproteinase (MT1-MMP, MMP-14) in prostate cancer cell lines.33 Thus, further work is necessary to evaluate the full mechanisms by which Sp1 exerts its proinvasion effects in glioma. The data derived from the mechanistic investigation of this study provide a possible explanation for the observed relevance of Sp1 overexpression to predicting the prognosis of human glioma. It would also be of great interest to investigate whether similar molecular cascade, namely, upregulation of MMP-2 by Sp1 overexpression, is also present in other caner types than gliomas.

In summary, our study indicates that Sp1 is an independent prognostic marker for human glioma and that its deregulated expression may contribute to glioma progression by enhancing MMP-2 expression and tumor invasion. It is hoped that these findings will provide new insights in the development of novel antiglioma strategies.


  1. Top of page
  2. Abstract
  3. Material and Methods
  4. Results
  5. Discussion
  6. References
  • 1
    Wick W, Platten M, Weller M. New (alternative) temozolomide regimens for the treatment of glioma. Neuro-onco 2009; 11: 6979.
  • 2
    Yang L, Ng KY, Lillehei KO. Cell-mediated immunotherapy: a new approach to the treatment of malignant glioma. Cancer Control 2003; 10: 13847.
  • 3
    Rivera AL, Pelloski CE, Sulman E, Aldape K. Prognostic and predictive markers in glioma and other neuroepithelial tumors. Curr Probl Cancer 2008; 32: 97123.
  • 4
    Dynan WS, Tjian R. The promoter-specific transcription factor Sp1 binds to upstream sequences in the SV40 early promoter. Cell 1983; 35: 7987.
  • 5
    Kadonaga JT, Courey AJ, Ladika J, Tjian R. Distinct regions of Sp1 modulate DNA binding and transcriptional activation. Science 1988; 242: 156670.
  • 6
    Safe S, Abdelrahim M. Sp transcription factor family and its role in cancer. Eur J Cancer 2005; 41: 243848.
  • 7
    Zannetti A, Del Vecchio S, Carriero MV, Fonti R, Franco P, Botti G, D'Aiuto G, Stoppelli MP, Salvatore M. Coordinate up-regulation of Sp1 DNA-binding activity and urokinase receptor expression in breast carcinoma. Cancer Res 2000; 60: 154651.
  • 8
    Chiefari E, Brunetti A, Arturi F, Bidart JM, Russo D, Schlumberger M, Filetti S. Increased expression of AP2 and Sp1 transcription factors in human thyroid tumors: a role in NIS expression regulation? BMC Cance 2002; 2: 35.
  • 9
    Yao JC, Wang L, Wei D, Gong W, Hassan M, Wu TT, Mansfield P, Ajani J, Xie K. Association between expression of transcription factor Sp1 and increased vascular endothelial growth factor expression, advanced stage, and poor survival in patients with resected gastric cancer. Clin Cancer Res 2004; 10: 410917.
  • 10
    Kumar AP, Butler AP. Enhanced Sp1 DNA-binding activity in murine keratinocyte cell lines and epidermal tumors. Cancer Lett 1999; 137: 15965.
  • 11
    Shi Q, Le X, Abbruzzese JL, Peng Z, Qian CN, Tang H, Xiong Q, Wang B, Li XC, Xie K. Constitutive Sp1 activity is essential for differential constitutive expression of vascular endothelial growth factor in human pancreatic adenocarcinoma. Cancer Res 2001; 61: 414354.
  • 12
    Giese A, Bjerkvig R, Berens ME, Westphal M. Cost of migration: invasion of malignant gliomas and implications for treatment. J Clin Oncol 2003; 21: 162436.
  • 13
    Forsyth PA, Wong H, Laing TD, Rewcastle NB, Morris DG, Muzik H, Leco KJ, Johnston RN, Brasher PM, Sutherland G, Edwards DR. Gelatinase-A (MMP-2), gelatinase-B (MMP-9) and membrane type matrix metalloproteinase-1 (MT1-MMP) are involved in different aspects of the pathophysiology of malignant gliomas. Br J Cancer 1999; 79: 182835.
  • 14
    VanMeter TE, Rooprai HK, Kibble MM, Fillmore HL, Broaddus WC, Pilkington GJ. The role of matrix metalloproteinase genes in glioma invasion: co-dependent and interactive proteolysis. J Neurooncol 2001; 53: 21335.
  • 15
    Uhm JH, Dooley NP, Villemure JG, Yong VW. Glioma invasion in vitro: regulation by matrix metalloprotease-2 and protein kinase C. Clin Exp Metastasis 1996; 14: 42133.
  • 16
    Qin L, Liao L, Redmond A, Young L, Yuan Y, Chen H, O'Malley BW, Xu J. The AIB1 oncogene promotes breast cancer metastasis by activation of PEA3-mediated matrix metalloproteinase 2 (MMP-2) and MMP9 expression. Mol Cell Biol 2008; 28: 593750.
  • 17
    Liu L, Wu J, Ying Z, Chen B, Han A, Liang Y, Song L, Yuan J, Li J, Li M. Astrocyte elevated gene-1 upregulates matrix metalloproteinase-9 and induces human glioma invasion. Cancer Res 2010; 70: 37509.
  • 18
    Pan MR, Hung WC. Nonsteroidal anti-inflammatory drugs inhibit matrix metalloproteinase-2 via suppression of the ERK/Sp1-mediated transcription. J Biol Chem 2002; 277: 3277580.
  • 19
    Li J, Guan HY, Gong LY, Song LB, Zhang N, Wu J, Yuan J, Zheng YJ, Huang ZS, Li M. Clinical significance of sphingosine kinase-1 expression in human astrocytomas progression and overall patient survival. Clin Cancer Res 2008; 14: 69967003.
  • 20
    Hahn WC, Dessain SK, Brooks MW, King JE, Elenbaas B, Sabatini DM, DeCaprio JA, Weinberg RA. Enumeration of the simian virus 40 early region elements necessary for human cell transformation. Mol Cell Biol 2002; 22: 211123.
  • 21
    Bouwman P, Philipsen S. Regulation of the activity of Sp1-related transcription factors. Mol Cell Endocrinol 2002; 195: 2738.
  • 22
    Black AR, Black JD, Azizkhan-Clifford J. Sp1 and krüpel-like factor family of transcription factors in cell growth regulation and cancer. J Cell Physiol 2001; 188: 14360.
  • 23
    Nicolás M, Noé V, Jensen KB, Ciudad CJ. Cloning and characterization of the 5′-flanking region of the human transcription factor Sp1 gene. J Biol Chem 2001; 276: 2212632.
  • 24
    Johnson-Pais T, Degnin C, Thayer MJ. pRB induces Sp1 activity by relieving inhibition mediated by MDM2. Proc Natl Acad Sci USA 2001; 98: 22116.
  • 25
    Wierstra I. Sp1: emerging roles–beyond constitutive activation of TATA-less housekeeping genes. Biochem Biophys Res Commun 2008; 372: 113.
  • 26
    Hoelzinger DB, Demuth T, Berens ME. Autocrine factors that sustain glioma invasion and paracrine biology in the brain microenvironment. J Natl Cancer Inst 2007; 99: 158393.
  • 27
    Hidalgo M, Eckhardt SG. Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl Cancer Inst 2001; 93: 17893.
  • 28
    Bae IH, Park MJ, Yoon SH, Kang SW, Lee SS, Choi KM, Um HD. Bcl-w promotes gastric cancer cell invasion by inducing matrix metalloproteinase-2 expression via phosphoinositide 3-kinase, Akt, and Sp1. Cancer Res 2006; 66: 49915.
  • 29
    Ishibashi H, Nakagawa K, Onimaru M, Castellanous EJ, Kaneda Y, Nakashima Y, Shirasuna K, Sueishi K. Sp1 decoy transfected to carcinoma cells suppresses the expression of vascular endothelial growth factor, transforming growth factor β1, and tissue factor and also cell growth and invasion activities. Cancer Res 2000; 60: 65316.
  • 30
    Jungert K, Buck A, von Wichert G, Adler G, König A, Buchholz M, Gress TM, Ellenrieder V. Sp1 is required for transforming growth factor-β-induced mesenchymal transition and migration in pancreatic cancer cells. Cancer Res 2007; 67: 156370.
  • 31
    Chen YJ, Chang WM, Liu YW, Lee CY, Jang YH, Kuo CD, Liao HF. A small-molecule metastasis inhibitor, norcantharidin, downregulates matrix metalloproteinase-9 expression by inhibiting Sp1 transcriptional activity in colorectal cancer cells. Chem Biol Interact 2009; 181: 4406.
  • 32
    Sen T, Dutta A, Maity G, Chatterjee A. Fibronectin induces matrix metalloproteinase-9 (MMP-9) in human laryngeal carcinoma cells by involving multiple signaling pathways. Biochimie 2010; 92: 142234.
  • 33
    Sroka IC, Nagle RB, Bowden GT. Membrane-type 1 matrix metalloproteinase is regulated by sp1 through the differential activation of AKT. J. NK, and. ERK pathways in human prostate tumor cells. Neoplasia 2007; 9: 40617.